#Amgen (AMGN) - Prohost Biotech

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen ( AMGN ) announced top-line results from two Repatha® (evolocumab) open label extension ( OLE ) studies to the Phase 3 FOURIER cardiov...

P

Prohost Biotech

Apr 27, 2022

What Happened Over the Past Two Days and Biotech

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United States’ government decided to ban the importation of Russian oil, liquefied natural gas and coal. This decision...

P

Prohost Biotech

Mar 10, 2022

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

Amgen Announces Positive Results from Otezla Study for Psoriasis Amgen ( AMGN ) announced positive top-line results from the DISCREET trial - a Phase 3, multicenter, randomized, placebo-controlled, do...

P

Prohost Biotech

Dec 2, 2021

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

Amgen Announced FDA Approval of LUMAKRAS ™ Amgen ( AMGN ) announced the news about the FDA approval of LUMAKRAS™ (sotorasib) on May 28, 2021. The firm indicated that the FDA granted approval is for...

P

Prohost Biotech

May 31, 2021

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR Tezepelum...

P

Prohost Biotech

May 14, 2021

CureVac N.V.

Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. ( CVAC ) , when the company announced business updates and financi...

P

Prohost Biotech

Apr 18, 2021

Amgen is Still the King of the Biotech Sector

Amgen KRAS Inhibitor, Sotorasib Amgen ( AMGN ) has taken on one of the toughest challenges in the last 40 years when it comes to cancer research by developing the KRAS inhibitor, sotorasib . This prod...

P

Prohost Biotech

Jan 30, 2021

Cytokinetics Product Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction

Cytokinetics Omecamtiv Mecarbil for Heat Failure Three biotech firms: Amgen ( AMGN ) , Cytokinetics ( CYTK ) and Servier worked on the Phase 3 GALACTIC-HF clinical trial to find out whether omecamtiv...

P

Prohost Biotech

Oct 13, 2020

Amgen's KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

Amgen and the KRAS G12C Protein Discovery The RAS gene family has been a subject for four decades of research. The family contains some of the most frequently mutated oncogenes in human cancers. Tar...

P

Prohost Biotech

Sep 25, 2020

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX ( CTMX ) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® techno...

P

Prohost Biotech

Apr 30, 2020

A Synopsis of Some Biotech Companies' Events

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen ( AMGN ) : The stock gained over $10 yester...

P

Prohost Biotech

Feb 6, 2020

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

As the Market Seems to Soar Our Eyes Are on the Following Biotech Firms: Amgen ( AMGN ) : A rebounding is expected following an unwarranted decline. Gilead Sciences ( GILD ) : A lot of good news fro...

P

Prohost Biotech

Feb 4, 2020

Prohost Letter #438 ~ The End of the Year Issue 2019

Prohost Letter #438 End of the Year Issue 2019 Happy New Year 2020 The NASDAQ reached 9000 for the first time in the market history on December 30, 2019. However, on the last trading day of 2019, the...

P

Prohost Biotech

Jan 1, 2020

The Week in Review #48 ~ Holiday Edition

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You a Happy New Year Filled with Excellent Health, Peace of Mind, Prosperity and Happiness What...

P

Prohost Biotech

Dec 27, 2019

Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ ( NKTR ) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology ( ASH ) Annual Meet...

P

Prohost Biotech

Dec 11, 2019

About the Prohost Portfolio Tables

Firstly, Forty-Seven and IVERIC bio We remind that the two condemned stocks Forty-Seven ( FTSV ) and IVERIC bio ( ISEE ) have continued to outperform since the day they managed to prove their lead...

P

Prohost Biotech

Dec 5, 2019

What A Week For Biotechnology

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” there is no complicated scientific and clinical information, leaving the details to the articles that we usually...

P

Prohost Biotech

Nov 11, 2019

The Quarterly Financial Results

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and investors relied on for years to evaluate biotech firms, including development stage firms, see...

P

Prohost Biotech

Nov 4, 2019

This Past Week

The Week in Review #43 This Past Week After hearing hints about the trade war between China and the United States being avoided the market reversed course from faltering to flying at the speed of ligh...

P

Prohost Biotech

Oct 22, 2019

News from NKTR, BMY and MRK. See Also: Biotechs' Bizarre Performances in Early Trading Hours Today

News from Nektar Nektar Therapeutics ( NKTR ) announced that new data from patients with metastatic triple-negative breast cancer, who were enrolled in the PIVOT-02 study, will be presented at the upc...

P

Prohost Biotech

Sep 24, 2019

1m

3